LEO Pharma gears for growth with senior leadership changes
LEO Pharma is excited to announce strategic leadership changes to bolster growth, further professionalize the organization, and strengthen its commitment to strategy and transformation. Kristian Sibilitz has been appointed as the new Executive Vice President (EVP) of Technical Development and Supply and will join the Global Leadership Team on December 1, 2024. Effective immediately, Jean Monin, EVP of Thrombosis, and Anne Jensen, Vice President (VP) of Strategy, will also join the Global Leadership Team. Additionally, Anders Monrad Rendtorff will join as the new head of Global Communications.
Ballerup, 7 November 2024 - With the announcement of three new members to the Global Leadership Team and a new head of Global Communications, LEO Pharma is taking another important step towards further professionalizing the organization and realizing its strategy to become the leader in medical dermatology.
Kristian Sibilitz will take up the position as EVP, Technical Development and Supply and member of the Global Leadership Team on 1 December 2024. He replaces Sven Hauptmann, who has decided to resign from LEO Pharma to join a Swiss company. Sven Hauptmann will leave by 30 November 2024.
Kristian Sibilitz brings extensive experience to LEO Pharma, having spent over 19 years at H. Lundbeck A/S in various leadership roles within Product Development and Supply. Currently, he is the Senior Vice President (SVP) of Pharmaceutical Production and Supply Chain, overseeing manufacturing, packaging, supply chain planning, and global distribution. A Danish citizen, Kristian holds a Master of Science in Supply Chain Management from the Technical University of Denmark, DTU.
CEO, Christophe Bourdon said: “We are pleased to welcome Kristian to the Global Leadership Team, where his extensive expertise and strong track record will be highly valued. At the same time, I would like to extend my sincere gratitude to Sven for his remarkable efforts in delivering safe and innovative products to patients, which have been unparalleled.”
In addition, Jean Monin, EVP of thrombosis, and Anne Jensen, VP, who leads LEO Pharma's strategy team, will also join the Global Leadership Team.
CEO Christophe Bourdon said, “I am delighted to welcome Jean and Anne to the Global Leadership Team. Jean has demonstrated proven success as a commercial leader, driving excellent results across the Thrombosis Global Business Unit in recent quarters. With Jean’s commercial expertise and Anne’s achievements in sharpening LEO Pharma’s strategy, they are both well-positioned to enhance our strategic execution and optimize LEO Pharma’s ability to capitalize on both present and future opportunities.”
Additionally, Anders Monrad Rendtorff will join LEO Pharma as SVP for Global Communications. Anders Monrad Rendtorff brings extensive experience to LEO Pharma, having worked for large, listed companies such as Coloplast and Vestas.
Kontakter
For further information please contact:
Media: Jeppe Ilkjær, mobile +45 3050 2014
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of approx. 4,000 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma continues to deliver double-digit revenue growth backed by strong dermatology sales31.10.2024 14:00:00 CET | Pressemeddelelse
Q3 2024 Trading Update (Unaudited)
LEO Pharma lancerer Anzupgo® (delgocitinib) creme i hjemmemarkedet Danmark som det andet land i verden28.10.2024 12:00:00 CET | Pressemeddelelse
Efter Europa Kommissionens produktgodkendelse i september bliver Danmark det næste og kun andet land i verden, hvor LEO Pharma lancerer sit nyeste lægemiddel, Anzupgo® (delgocitinib) creme, efter lanceringen i Tyskland tidligere på måneden. (1) Anzupgo® creme er den første godkendte topikale behandling for voksne med moderat til svært kronisk håndeksem, hvor topikale kortikosteroider er utilstrækkelige eller uhensigtsmæssige. (1) Lanceringen giver en ny behandlingsmulighed for de mange voksne danskere, som lever med moderat til svært kronisk håndeksem, som er en af de mest udbredte kroniske inflammatoriske hudsygdomme, der rammer 4,7% af befolkningen. (2,3)
Germany Becomes the First Country to Launch LEO Pharma’s Anzupgo® (delgocitinib) Cream15.10.2024 09:00:00 CEST | Pressemeddelelse
Following the recent European Commission (EC) approval, Germany has become the first country worldwide where Anzupgo will be made available.(1) Anzupgo is the first topical treatment specifically indicated for adults with moderate to severe Chronic Hand Eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.(1) The launch brings a new treatment option for the estimated 3.9 million people in Germany living with CHE, a condition with a high unmet need for which no specifically approved topical treatment was previously available.(2,3)
LEO Pharma commits to net-zero greenhouse gas emissions by 205011.10.2024 11:00:00 CEST | Pressemeddelelse
A net-zero target is a natural continuation of our current commitments to run a sustainable business, LEO Pharma says.
LEO Pharma Presents Late-breaking Tralokinumab Data at EADV 2024 for Moderate-to-Severe Atopic Dermatitis (AD) in the Difficult-to-Treat Head and Neck Region27.9.2024 15:00:00 CEST | Pressemeddelelse
Real-world findings showed that subgroup of patients treated with Adtralza® (tralokinumab) / Adbry® (tralokinumab-ldrm) and with head and neck (H&N) atopic dermatitis (AD) at baseline reported presence of AD in that area in 52.1% of patients after nine months of treatment.(1) As part of one of LEO Pharma’s most extensive scientific programs at EADV to date, the late-breaking presentation examined interim data from the real-world TRACE study of adult AD patients who have been prescribed Adtralza/Adbry for up to nine months.(1) Additional posters presented interim results of the TRACE study on effectiveness of Adtralza/Adbry treatment through various physician and patient reported outcomes such as improvements in Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), itch, sleep disturbance and quality of life.(2,3)
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum